Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 426

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

Open access
Cervantes, Francisco, Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Al-Ali, Haifa Kathrin, Sirulnik, Andres, Stalbovskaya, Viktoriya, McQuitty, Mari, Hunter, Deborah S., Levy, Richard S., Passamonti, Francesco, Barbui, Tiziano, Barosi, Giovanni, Harrison, Claire N., Knoops, Laurent, Gisslinger, Heinz·2013·Blood

Abstract

Key Points: Long-term analysis of the COMFORT-II Trial shows that ruxolitinib treatment results in durable reductions in splenomegaly and is well tolerated. Patients randomized to ruxolitinib showed longer overall survival than those receiving the BAT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2013-02-485888

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 426

Metadata

Authors
Cervantes, F., Vannucchi, A. M., Kiladjian, J.-J., Al-Ali, H. K., Sirulnik, A., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R. S., Passamonti, F., Barbui, T., Barosi, G., Harrison, C. N., Knoops, L., & Gisslinger, H.
Venue
Blood
Published
2013-12-12
Volume
122
Issue
25
Pages
4047-4053
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2018254868
Cited by
426
References
13
FWCI
28.10
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. https://app.cochat.ai/papers/10.1182/blood-2013-02-485888
The paper
Cervantes, F., Vannucchi, A. M., Kiladjian, J.-J., Al-Ali, H. K., Sirulnik, A., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R. S., Passamonti, F., Barbui, T., Barosi, G., Harrison, C. N., Knoops, L., & Gisslinger, H. (2013). Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. https://doi.org/10.1182/blood-2013-02-485888

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.